The company plans to talk to the U.S. Food and Drug Administration about seeking approval for the vaccine. Image used for representational purposes only | Photo Credit: Getty Images Sellas Life Sciences said on Tuesday, November 17, 2026 that its experimental vaccine helped patients with a type of blood cancer live longer in a late-stage trial.The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow.Patients who received GPS lived a median of 24 months, compared to 14.7 months for those given the best available treatment, Sellas said.The company plans to talk to the U.S. Food and Drug Administration about seeking approval for the vaccine. Its shares were halted in premarket trading. Published - November 19, 2026 04:35 pm IST
Sellas’ cancer vaccine extends survival in blood cancer trial, company says
Full Article
Original Source
Read the full article at Thehindu →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.